🇺🇸#TEVA #отчетность
Teva
Q3 Non-GAAP EPS of $0.59 misses by $0.03.
Revenue of $3.6B (-7.7% Y/Y) misses by $250M.
FY2022 Outlook: Revenues of $14.8B - $15.4B vs. previous range of $15B - $15.6B vs. consensus of $15.33B; Adjusted EBITDA of $4.7B - $5B; Non-GAAP diluted EPS of $2.40 - $2.60 vs. consensus of $2.54; Free cash flow of $1.9B - $2.2B; Non-GAAP tax rate of 12% - 14% vs. previous range of 13%-14%.
Teva
Q3 Non-GAAP EPS of $0.59 misses by $0.03.
Revenue of $3.6B (-7.7% Y/Y) misses by $250M.
FY2022 Outlook: Revenues of $14.8B - $15.4B vs. previous range of $15B - $15.6B vs. consensus of $15.33B; Adjusted EBITDA of $4.7B - $5B; Non-GAAP diluted EPS of $2.40 - $2.60 vs. consensus of $2.54; Free cash flow of $1.9B - $2.2B; Non-GAAP tax rate of 12% - 14% vs. previous range of 13%-14%.